2-[(4-Hydroxy-3,5-dimethylphenyl)methyl]-4-[4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidin-1-yl]-1-(4-piperidin-1-ylpiperidin-1-yl)butane-1,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[(4-Hydroxy-3,5-dimethylphenyl)methyl]-4-[4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidin-1-yl]-1-(4-piperidin-1-ylpiperidin-1-yl)butane-1,4-dione
• 化学式: C₃₆H₄₉N₅O₄
• 分子量: 615.8
• InChiKey: ZHMHRAHEGZLECS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  45
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  96.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20010036946A1

  公开（公告）日：2001-11-01

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改良氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5中所定义，它们的互变异构体、对映异构体、混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及用于制备它们的过程，以及它们在抗体的生产和纯化中的用途，以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• Modified aminoacids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20030069231A1

  公开（公告）日：2003-04-10

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改性氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5所定义，它们的互变异构体、对映异构体、混合物和盐，特别是它们与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的制药组合物，其使用和制备过程，以及它们在抗体的生产和纯化中的使用，作为RIA和ELISA测定中的标记化合物，以及在神经递质研究中作为诊断或分析辅助工具的使用。
• Pharmaceutical composition for intranasal administration containing a CGRP antagonist
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040076587A1

  公开（公告）日：2004-04-22

  The invention relates to pharmaceutical compositions for nasal application, comprising selected CGRP antagonists which are described in WO 98/11128, as well as a process for the preparation thereof.

  本发明涉及用于鼻腔的药物组合物，其中包含 WO 98/11128 中所述的精选 CGRP 拮抗剂及其制备方法。
• Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
  申请人：Doods Henri

  公开号：US20050032783A1

  公开（公告）日：2005-02-10

  The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a CGRP antagonist and/or of a CGRP release inhibitor to the patient, and to the use of said active compounds for the manufacture of a pharmaceutical composition intended to be used in this method.

  本发明涉及一种治疗或预防因前列腺癌治疗中的雄激素消融治疗等原因而接受阉割的男性潮热的方法，包括向患者施用有效量的CGRP拮抗剂和/或CGRP释放抑制剂，以及使用所述活性化合物制造用于该方法的药物组合物。
• CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
  申请人：Doods Henri

  公开号：US20050233980A1

  公开（公告）日：2005-10-20

  The present invention relates to a process for the treatment or prevention of headaches, migraine or cluster headache, this process comprising the joint administration of a therapeutically effective amount of the CGRP-antagonist (A) or a physiologically acceptable salt thereof and a therapeutically effective amount of the selective serotonin reuptake inhibitor (B) or a physiologically acceptable salt thereof, as well as the corresponding pharmaceutical compositions and the preparation thereof.

  本发明涉及一种治疗或预防头痛、偏头痛或丛集性头痛的方法，该方法包括联合给药治疗有效量的CGRP-拮抗剂（A）或其生理学上可接受的盐和治疗有效量的选择性5-羟色胺再摄取抑制剂（B）或其生理学上可接受的盐，以及相应的药物组合物及其制备方法。